Genetic Technologies Provides Update on Board and Management

Genetic Technologies Provides Update on Board and Management Changes 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 11/29/12 --   Genetic
Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today the
appointment of Dr. Mal Brandon to the position of Chairman. In
addition, Ms. Alison Mew, the Company's Chief Operating Officer will
now serve as Acting Chief Executive Officer and Mr. Tom Howitt will
continue in his role as Chief Financial Officer. These appointments
follow the departure of Directors, Dr. Mel Bridges, Mr. Huw Jones and
Mr. Greg Brown along with Dr. Paul MacLeman, Chief Executive Officer. 
"On behalf of the Board and management team, I wish to extend our
gratitude to the departing Directors for their service and, in
particular, to Paul MacLeman who was integral in transforming Genetic
Technologies into a commercial stage women's health company. Moving
forward, the strategy for corporate growth remains unchanged as we
continue to ramp-up BREVAGen(TM) sales and our overall U.S.
operations while driving the Company's successful global licensing
program," commented Dr. Mal Brandon, Chairman of Genetic
Technologies. 
The departure of the aforementioned Directors and Chief Executive
Officer was announced on November 27th as part of the Company's
Annual General Meeting results held on November 26th in Melbourne,
Australia. 
About BREVAGen(TM)
 The BREVAGen(TM) breast cancer risk
stratification test is a novel genetic test panel that examines a
patient's DNA to detect the absence or presence of certain common
genetic variations (SNPs) associated with an increased risk for
developing breast cancer. The test is designed to help physicians
assess aggregate breast cancer risk from these genetic markers, plus
factors from a standard clinical assessment based on a patient's
family and personal history, thus giving a clearer picture of an
individual woman's risk of developing breast cancer. The BREVAGen(TM)
test may be especially useful for women predisposed to hormone
dependant breast cancer, including those who have undergone breast
biopsies, as the test will provide information that can help
physicians recommend alternative courses of action, such as more
vigilant, targeted surveillance or preventive therapy, on a
personalized patient-by-pati
ent basis. For more information, please
visit http://www.brevagen.com, or http://www.brevagen.com.au  
About Genetic Technologies Limited
 Genetic Technologies is an
established diagnostics company with more than 20 years of experience
in commercializing genetic testing, non-coding DNA and product
patenting. The Company has operations in Australia and the U.S. and
is dual-listed on the ASX (GTG.AX) and NASDAQ (GENE). Genetic
Technologies is focused on the commercialization of its patent
portfolio through an active out-licensing program and the global
expansion of its oncology and cancer management diagnostics assets.
Its U.S. subsidiary, Phenogen Sciences, offers novel predictive
testing and assessment tools to help physicians proactively manage
women's health. Phenogen's lead product, BREVAGen(TM), is a first in
class, clinically validated risk assessment test for non-familial
breast cancer. For more information, please visit
http://www.gtglabs.com, or http://www.phenogensciences.com. 
Safe Harbor Statement
 Any statements in this press release that
relate to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act
The Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting certain
cases brought under the federal securities laws, including changes
related to pleading, discovery, liability, class representation and
awards fees. Since this information may involve risks and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results.
Additional risks associated with Genetic Technologies' business can
be found in its periodic filings with the SEC. 
FOR FURTHER INFORMATION PLEASE CONTACT
Tom Howitt
Chief Financial Officer
Genetic Technologies Limited
Phone: +61 3 8412 7050 
Rudi Michelson (Australia)
Monsoon Communications 
(03) 9620 3333 
Laura Landry (USA)
Blueprint Life Science Group
+1 (415) 375.3340 Ext. 103